Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 9421250
Pathogenic phlebovirus isolates and compositions and methods of use
granted -
US 9422223
Compounds and methods for delivery of prostacyclin analogs
granted -
US 9421254
Immunostimulatory combinations of TLR ligands and methods of use
granted -
US 9415099
Method of altering the immundominance hierarchy of HIV gag by DNA vaccine expressing conserved regions
granted -
US 9415105
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
granted -
US 9416190
Mesothelin antibodies and methods for eliciting potent antitumor activity
granted -
US 9415116
Compositions and methods for delivering inhibitory oligonucleotides
granted -
US 9408896
Vaccination of companion animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission
granted -
US 9409994
High-affinity monoclonal antibodies to glypican-3 and use thereof
granted -
US 9409992
Mesothelin domain-specific monoclonal antibodies and use thereof
granted -
US 9409956
Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof
granted -
US 9408901
Compositions, methods and uses for dengue virus serotype-4 constructs
granted -
US 9403872
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
granted -
US 9402820
Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
granted -
US 9402889
Live, oral vaccine for protection against Shigella dysenteriae serotype 1
granted -
US 9399625
Acridone compounds
granted -
US 9399672
Hepatitis C virus neutralizing antibody
granted -
US 9394364
Human monoclonal antibodies specific for glypican-3 and use thereof
granted -
US 9394316
Inhibitors of the plasmodial surface anion channel as antimalarials
granted -
US 9393271
GHRH agonists for islet cell transplantation and function and the treatment of diabetes
granted -
US 9394352
Immunogenic POTE peptides and methods of use
granted -
US 9394358
Gene signature for predicting prognosis of patients with solid tumors
granted -
US 9387214
Method of identifying therapies for pulmonary hypertension
granted -
US 9388222
Modified Pseudomonas exotoxin A
granted -
US 9387224
Treatment of specific cardiovascular conditions with nitrite
granted -
US 9388221
Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
granted -
US 9382302
Lutzomyia longipalpis polypeptides and methods of use
granted -
US 9382311
HIV-1 broadly neutralizing antibodies
granted -
US 9382547
Human optimized Bacillus anthracis protective antigen
granted -
US 9375424
Compounds that treat malaria and prevent malaria transmission
granted -
US 9375438
Inhibitors of NCCa-ATP channels for therapy
granted -
US 9370559
Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
granted -
US 9364448
Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
granted -
US 9364557
Fold-back diabody diphtheria toxin immunotoxin and methods of use
granted -
US 9365612
Caspase inhibitors
granted -
US 9365626
Simukunin
granted -
US 9358240
Treprostinil administration by inhalation
granted -
US 9359418
Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
granted -
US 9359447
Anti-mesothelin chimeric antigen receptors
granted -
US 9358306
Photosensitizing antibody-fluorophore conjugates
granted -
US 9358285
Granulysin in immunotherapy
granted -
US 9352011
Method and composition for synchronizing time of insemination
granted -
US 9352032
Live attenuated antigenically marked classical swine fever vaccine
granted -
US 9353117
Substituted pyrazolopyrimidines as glucocerebrosidase activators
granted -
US 9353353
Virus-like particles (VLPs) prepared from chikungunya virus structural proteins
granted -
US 9345748
Anti-SSX-2 T cell receptors and related materials and methods of use
granted -
US 9346859
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
granted -
US 9347951
Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory